|
⚲
|
| Keyboard |
| Decheng Capital Global Life Sciences Fund IV LP
✚
|
|
|---|---|
| CIK # | 0001834150 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001834150] | |
| 4 | [0001834150] | |
| D | [0001834150] | |
| SC 13D | [0001834150] | |
| SC 13G | [0001834150] |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Aardvark Therapeutics Inc AARD
Common Stock
|
2025-02-14 | Conversion | 2,333,887 | ||
|
Aardvark Therapeutics Inc AARD
Common Stock
|
2025-02-14 | Buy | 625,000 | $16.00 | 10,000,000 |
|
Aardvark Therapeutics Inc AARD
Common Stock
|
2025-02-14 | Buy | 625,000 | $16.00 | 10,000,000 |
|
Aardvark Therapeutics Inc AARD
Common Stock
|
2025-02-14 | Conversion | 333,412 | ||
|
Aardvark Therapeutics Inc AARD
Series C Convertible Preferred Stock · derivative
|
2025-02-14 | Conversion | 19,777,363 | $0.00 | |
|
Aardvark Therapeutics Inc AARD
Series C Convertible Preferred Stock · derivative
|
2025-02-14 | Conversion | 2,825,337 | $0.00 | |
|
CG Oncology Inc CGON
Common Stock
|
2024-01-29 | Conversion | 3,628,198 | ||
|
CG Oncology Inc CGON
Common Stock
|
2024-01-29 | Buy | 400,000 | $19.00 | 7,600,000 |
|
CG Oncology Inc CGON
Series C Preferred Stock · derivative
|
2024-01-29 | Conversion | 8,644,891 | ||
|
CG Oncology Inc CGON
Series F Preferred Stock · derivative
|
2024-01-29 | Conversion | 4,402,320 | ||
|
CG Oncology Inc CGON
Series E Preferred Stock · derivative
|
2024-01-29 | Conversion | 21,547,685 |